Home › Compare › EQRXW vs PLD

EQRXW vs PLD: Dividend Comparison 2026

EQRXW yields 4395.60% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EQRXW wins by $17844003331683.54M in total portfolio value
10 years
EQRXW
EQRXW
● Live price
4395.60%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$17844003331690.04M
Annual income
$17,079,643,292,413,290,000.00
Full EQRXW calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — EQRXW vs PLD

📍 EQRXW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEQRXWPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EQRXW + PLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
EQRXW pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EQRXW
Annual income on $10K today (after 15% tax)
$373,626.37/yr
After 10yr DRIP, annual income (after tax)
$14,517,696,798,551,296,000.00/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, EQRXW beats the other by $14,517,696,798,546,827,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EQRXW + PLD for your $10,000?

EQRXW: 50%PLD: 50%
100% PLD50/50100% EQRXW
Portfolio after 10yr
$8922001665848.27M
Annual income
$8,539,821,646,209,274,000.00/yr
Blended yield
95.72%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

EQRXW
No analyst data
Altman Z
9.5
Piotroski
1/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EQRXW buys
0
PLD buys
0
No recent congressional trades found for EQRXW or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEQRXWPLD
Forward yield4395.60% ✓3.18%
Annual dividend / share$2.00$4.10 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4% ✓
Portfolio after 10y$17844003331690.04M ✓$6.50M
Annual income after 10y$17,079,643,292,413,290,000.00 ✓$5,256,436.18
Total dividends collected$17792054110403.60M ✓$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: EQRXW vs PLD ($10,000, DRIP)

YearEQRXW PortfolioEQRXW Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$450,260$439,560.44$11,255$555.24+$439.0K → EQRXW
2$18,978,664$18,496,885.68$13,062$1,018.59+$18.97M → EQRXW
3$748,953,345$728,646,173.66$15,903$1,926.67+$748.94M → EQRXW
4$27,674,743,815$26,873,363,736.79$20,839$3,823.32+$27674.72M → EQRXW
5$957,652,835,286$928,040,859,403.20$30,464$8,166.08+$957652.80M → EQRXW
6$31,037,578,041,538$30,012,889,507,782.54$52,054$19,457.30+$31037577.99M → EQRXW
7$942,293,671,101,243$909,083,462,596,797.50$109,886$54,188.93+$942293670.99M → EQRXW
8$26,802,238,424,024,828$25,793,984,195,946,500.00$304,030$186,451.18+$26802238423.72M → EQRXW
9$714,355,176,894,161,700$685,676,781,780,455,000.00$1,166,125$840,813.32+$714355176893.00M → EQRXW
10$17,844,003,331,690,041,000$17,079,643,292,413,290,000.00$6,504,190$5,256,436.18+$17844003331683.54M → EQRXW

EQRXW vs PLD: Complete Analysis 2026

EQRXW — Stock

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. Its product pipeline in development includes Aumolertinib, an EGFR inhibitor for the treatment of ?EGFR-mutated? non-small cell lung cancer (NSCLC); Sugemalimab, an anti-PD-L1 antibody for the treatment of ?stage III and IV ?NSCLC; Lerociclib, a CDK4/6 inhibitor to treat HR+/HER2- breast cancer; and EQ176, an anti-PD-1?antibody for the treatment of liver cancer. The company has partnerships with Exscientia and AbCellera Biologics Inc. EQRx, Inc. was founded in 2020 and is based in Cambridge, Massachusetts.

Full EQRXW Calculator →

PLD — REIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this EQRXW vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EQRXW vs SCHDEQRXW vs JEPIEQRXW vs OEQRXW vs KOEQRXW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.